---
document_datetime: 2023-09-21 17:39:26
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/viraferon-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: viraferon-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.8759518
conversion_datetime: 2025-12-23 07:43:50.495404
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

<!-- image -->

| Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   Application number | Type of modification   | Notification/ Opinion issued on   | Commission Decision Issued/amen ded on   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------|-----------------------------------|------------------------------------------|
| Update of summary of product characteristics and package leaflet to bring the package leaflet in line with the text of the SPC regarding the dose for the melanoma induction therapy and the in-use storage conditions                                                                                                                                                                                                                                                                                                                    |                 0002 | II                     | 13.04.00                          | 28.08.00                                 |
| Minor change of manufacturing process of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                 0003 | I/II                   | 25.05.00                          | N/A                                      |
| New purification process for the interferon alfa-2-b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                 0004 | II                     | 27.07.00                          | N/A                                      |
| Changes in test procedures of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                 0005 | I/II                   | 23.06.00                          | 28.08.00                                 |
| Change in the batch size of finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0006 | I/II                   | 27.07.00                          | 28.08.00                                 |
| Minor changes in the manufacture of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                 0007 | I/II                   | 27.07.00                          | N/A                                      |
| Change in specifications of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0008 | I                      | 19.12.00                          | N/A                                      |
| Change in specifications of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0009 | I                      | 19.12.00                          | N/A                                      |
| Change in specifications of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0010 | I                      | 19.10.00                          | N/A                                      |
| Change in specifications of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0011 | longer I               | 19.10.00                          | N/A                                      |
| Change in specifications of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0012 | I                      | 19.12.00                          | N/A                                      |
| Change in the test procedures of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                 0013 | I                      | 19.12.00                          | N/A                                      |
| Change in the test procedures of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                 0014 | I                      | 04.01.01                          | N/A                                      |
| Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                 0015 | II                     | 20.09.01                          | 12.10.01                                 |
| Change in the batch size of finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0016 | I                      | 28.03.01                          | N/A                                      |
| Extension of shelf-life as foreseen at time of authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 0018 | I                      | 01.06.01                          | N/A                                      |
| no Update of the Summary of Product Characteristics (sections 4.4, 4.8) to include the adverse reactions: hypertriglyceridaemia and sarcoidosis as requested by the CPMP following the assessments of the second PSURs for Viraferon and ViraferonPeg; and to update corresponding text in the Package Leaflet. The Package Leaflet was also harmonised with the Summary of Product Characteristics with respect to the warning on aplastic anaemia. In addition changes were made to contact details of the local representatives in the |                 0019 | II                     | 17.01.02                          | 19.04.02                                 |
| Package Leaflet. Increase of the shelf-life of interferon alfa-2b, manufactured using the isoform conversion purification process, to 24 months.                                                                                                                                                                                                                                                                                                                                                                                          |                 0020 | I                      | 28.02.02                          | N/A                                      |
| product Tighten the E.coli protein release specification for Interferon alfa-2b drug substance manufactured using the Isoform Conversion Process. The Company has proposed to tighten the current release specification from 0.02% of total protein to less than or equal to 0.01% of total protein.                                                                                                                                                                                                                                      |                 0021 | I                      | 26.03.02                          | N/A                                      |
| Include the following two changes to the release and stability specifications for interferon alfa-2b drug substance: - Reverse phase HPLC purity test: introduction of release and stability specifications - SDS-PAGE: change of reducing and non reducing release and                                                                                                                                                                                                                                                                   |                 0022 | II                     | 25.07.02                          | N/A                                      |
| Increase of the retention time window for the integration of impurity peaks in the Viraferon Solution for Injection Vials RP-HPLC purity test.                                                                                                                                                                                                                                                                                                                                                                                            |                 0023 | I                      | 13.08.02                          | N/A                                      |
| Update of the SPC (sections 4.4, 4.8), to reinforce the warning and safety information with regard to ophthalmic disorders. A corresponding warning in the Package leaflet was also requested. Section 4.8 was also modified to indicate that reactions could occur with Intron A monotherapy as well as with combination therapy.                                                                                                                                                                                                        |                 0024 | II                     | 19.09.02                          | 05.12.02                                 |
| Medicinal Extend the currently approved in-use shelf-life from 12 days with a total of 6 injections (3 times a week) to 27 days with a total of 12 injections (3 times a week). As a consequence, the number of needles and swaps provided per pen must be doubled and new pack sizes are proposed as a consequential variation.                                                                                                                                                                                                          |                 0025 | I                      | 28.08.02                          | 10.10.02                                 |
| Update of the flow-charts of the secondary packaging sites.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                 0026 | I                      | 10.09.02                          | N/A                                      |

<div style=\"page-break-after: always\"></div>

| Replace the current Polysorbate 80 from animal origin used as an excipient for the drug product by Polysorbate 80 from vegetable origin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   0028 | I           | 22.11.02   | N/A            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------|------------|----------------|
| Additional supplier of HSA (Instituto Grifols S.A., Barcelona, Spain). The Marketing Authorisation Holder took the opportunity to change the pharmacopoeial reference to Ph. Eur. for Dibasic Sodium Phosphate Anhydrous.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |   0029 | II          | 19.03.03   | authorised N/A |
| Update of section 4.4 of the SPC to reinforce the warning on auto- immune disorders and to add a warning regarding HCV/HIV co- infected patients. A statement on the use of paracetamol was removed. Section 4.8 was updated to add the adverse events: Stevens Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Information on auto-immune and immune mediated disorders was also added. The MAH took the opportunity to bring section 4.8 into line with current guidelines with the consequential change of section 4.8 to a tabular format with the addition of adverse reactions occurring at the 1% level. A warning regarding the teratogenicity and embryocidicity of ribavirin was added to section 4.6 since the recommended use of Intron A in the treatment of hepatitis C is in combination with ribavirin. The term 'histologically proven' was deleted from 4.1 and a cross reference to a new warning in 4.4 inserted. Minor changes to section 4.2 were requested to remove a discrepancy between two statements. Corresponding changes were made to the Package Leaflet Introduction of a low control limit (in addition to the existing high |   0030 | II          | 25.04.03   | 29.07.03       |
| control limit) for the quantitiy of TCA precipitate used in the TCA precipitate extraction step of the interferon alfa-2b active substance purification process.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   0031 | longer I/II | 26.06.03   |                |

## Medicinal product no longer authorised Additional supplier of HSA (Instituto Grifols S.A., Barcelona, Spain). The Marketing Authorisation Holder took the opportunity to change the pharmacopoeial reference to Ph. Eur. for Dibasic Sodium Phosphate Anhydrous. Update of section 4.4 of the SPC to reinforce the warning on autoimmune  disorders  and  to  add  a  warning  regarding  HCV/HIV  coinfected  patients.    A  statement  on  the  use  of  paracetamol  was removed. Section 4.8 was updated to add the adverse events: Stevens Johnson syndrome,  toxic  epidermal  necrolysis  and  erythema  multiforme. Information  on  auto-immune  and  immune  mediated  disorders  was also added.  The MAH took the opportunity to bring section 4.8 into line with current guidelines with the consequential change of section 4.8  to  a  tabular  format  with  the  addition  of  adverse  reactions occurring at the 1% level. A  warning  regarding the teratogenicity and embryocidicity ribavirin  was  added  to  section  4.6  since  the  recommended  use  of Intron  A  in  the  treatment  of  hepatitis  C  is  in  combination  with ribavirin. The term 'histologically proven' was deleted from 4.1 and a cross reference to a new warning in 4.4 inserted. Minor changes to section 4.2 were requested to remove discrepancy between two statements. Corresponding changes were made to the Package Leaflet Introduction of a low control limit (in addition to the existing high control limit) for the quantitiy of TCA precipitate used in the TCA precipitate extraction step of the interferon alfa-2b active substance purification process.